Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study)
The PEX mRNA signature could be useful as a companion diagnostic of nivolumab. The combination of an anti-NKG2A antibody (i.e., monalizumab) and nivolumab may serve as a treatment option for non-survivors predicted by a RT-qPCR-based pre-treatment measurement of PEX mRNAs.
Authors
- Akihito Watanabe (ORCID: https://orcid.org/0000-0002-5403-4121)
- Kiyoaki Tsukahara (ORCID: https://orcid.org/0000-0002-4198-9615)
- Satoshi Kano (ORCID: https://orcid.org/0000-0003-4750-5332)
- Kuniaki Sato (ORCID: https://orcid.org/0000-0001-6014-1911)
- Hirohito Umeno (ORCID: https://orcid.org/0000-0002-2347-495X)
- Satoshi Toh (ORCID: https://orcid.org/0000-0003-1417-7563)
- Takeharu Ono (ORCID: https://orcid.org/0000-0003-2414-7034)
- Muneyuki Masuda (ORCID: https://orcid.org/0000-0002-7479-8356)
- Yukinori Asada (ORCID: https://orcid.org/0000-0002-8955-7168)
- Nobuhiro Hanai (ORCID: https://orcid.org/0000-0003-2524-8283)
- Nobuya Monden (ORCID: https://orcid.org/0000-0002-1119-028X)
- Takahiro Asakage
- Mioko Matsuo (ORCID: https://orcid.org/0000-0002-9158-1298)
- Shigemichi Iwae (ORCID: https://orcid.org/0000-0003-4011-6633)
- Takahiro Hongo (ORCID: https://orcid.org/0000-0003-0395-8946)
- Yushi Ueki (ORCID: https://orcid.org/0000-0002-1699-7891)
- Takafumi Nakano (ORCID: https://orcid.org/0000-0003-4298-2041)
- Ichiro Ota (ORCID: https://orcid.org/0000-0003-3815-8877)
- Daisuke Sano (ORCID: https://orcid.org/0000-0002-7686-4724)
- Tsutomu Ueda (ORCID: https://orcid.org/0000-0001-9771-3880)
- Kazuki Hashimoto (ORCID: https://orcid.org/0000-0002-8324-2202)
- Takahito Fukusumi (ORCID: https://orcid.org/0009-0002-1857-7548)
- Masashi Sugasawa
- Keisuke Yamazaki (ORCID: https://orcid.org/0000-0002-2320-2073)
- Hideoki Uryu (ORCID: https://orcid.org/0009-0002-3502-817X)
- Hiroyuki Ozawa (ORCID: https://orcid.org/0000-0002-4275-4105)
- Torahiko Nakashima (ORCID: https://orcid.org/0000-0002-8109-9174)
- Taku Murakami
- Takashi Maruo
Institutions
- Kurume University (JP)
- Hiroshima University (JP)
- Tokyo Medical and Dental University (JP)
- Kyushu University (JP)
- Tokyo Medical University (JP)
- Keio University (JP)
- Hokkaido University (JP)
- National Kyushu Medical Center (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Miyagi Prefectural Hospital Organization (JP)
- Keiyukai Sapporo Hospital (JP)
- Aichi Cancer Center (JP)
- Shikoku Cancer Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Nagoya University (JP)
- Nara Medical University (JP)
- Niigata University (JP)
- Saitama Medical University (JP)
- Yokohama City University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1464419
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00